Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer

Fig. 1

Impact of the expression of TFEB, ABCA1 and ABCC1 on NSCLC patients’ survival. (A-C) Kaplan Meyer analysis of overall survival (OS) of patients from the TGCA-LUAD cohort (n = 531), categorized according to the expression levels of TFEB (A), ABCA1 (B) and ABCC1 (C). (D) OS in TGCA-LUAD cohort patients, categorized in: TFEBhighABCA1highABCC1low, TFEBhighABCA1lowABCC1high, TFEBhighABCA1lowABCC1low, TFEBlowABCA1highABCC1high, TFEBlowABCA1highABCC1low, TFEBlowABCA1lowABCC1high, TFEBlowABCA1lowABCC1low. (E-H) Retrospective analysis of progression-free survival (PFS; E, G) and OS (F, H) in TFEBhighABCA1highABCC1low versus TFEBlowABCA1lowABCC1high patients, treated with cisplatin/carboplatin (Pt; n = 32) or pembrolizumab as immune checkpoint inhibitor (ICI; n = 43) at the Department of Oncology, University of Torino, Italy

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us